Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
US Army
McKesson
Covington
Daiichi Sankyo
Baxter
Deloitte
Queensland Health
Boehringer Ingelheim

Generated: April 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 4,189,469

« Back to Dashboard

Summary for Patent: 4,189,469
Title: Pharmaceutical compositions
Abstract:A pharmaceutical composition for oral administration in dosage unit form which comprises at least one xanthine derivative selected from the group consisting of (a) (.omega.-1(-hydroxyalkyl-dialkylxanthines wherein the (.omega.-1)-hydroxyalkyl group contains 5 or 6 carbon atoms and is in the 1- or 7-position, the alkyl group in the other of the 1- and 7-position contains from 1 to 12 carbon atoms and the alkyl group in the 3-position contains from 1 to 4 carbon atoms, (b) (.omega.-1)-oxoalkyl-dimethylxanthines wherein the (.omega.-1)-oxoalkyl group contains 5 or 6 carbon atoms and is in the 1- or 7-position, (c) dimethylxanthine derivatives having an additional alkyl group containing from 4 to 12 carbon atoms in the 1- or 7-position, and (d) dimethylxanthine derivatives having an additional benzyl group in the 1- or 7-position and a saliva forming agent, each dosage unit containing at least 300 mg of xanthine derivative, and the weight ratio of xanthine derivative to saliva forming agent being in the range from 1:2 to 10:1 and a method for the preparation of said composition.
Inventor(s): Gleixner; Klaus (Taunusstein-Wehen, DE), Muller; Roland (Wiesbaden, DE), Lehrach; Franz (Wiesbaden, DE)
Assignee: Hoechst Aktiengesellschaft (Frankfurt, DE)
Application Number:05/683,795
Patent Claim Types:
see list of patent claims
Composition; Dosage form; Process;

Drugs Protected by US Patent 4,189,469

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 4,189,469

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany2520978May 10, 1975

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Cipla
Accenture
QuintilesIMS
Merck
Argus Health
Cantor Fitzgerald
Harvard Business School
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.